Hydrogen peroxide as a potential marker for monitoring airway inflammation in severe asthma patients on biologics
Year: 2024
Type: conference-abstract
Abstract: Introduction: Monitoring biologic treatment response in severe asthmatics requires objective biomarkers, given limitations in assessing optimal control based mainly on symptoms and lung function. In this respect, we investigated a potential marker of airway inflammation, hydrogen peroxide (H2O2), measured by exhaled breath condensate (EBC). Materials and Methods: In this monocenter, prospective study, we assessed exhaled H2O2 levels in severe asthmatics on biologics and healthy controls with Inflammacheck® by Exhalation Technology. H2O2 fluctuations in asthmatics were explored over two weeks. Symptoms were defined as high vs. low-controlled based on asthma control questionnaires ACT and ACQ6. Low-control was defined as ACT≤19 and/or ACQ6≥1 and high-control: ACT>19 and/or ACQ6<1. WhitneyU test (p≤0.05) was used to compare H2O2 of high-controlled severe asthmatics and healthy controls. Results: In 16 severe asthmatics, there were no significant exhaled-H2O2 differences at baseline and after two weeks. Low-controlled patients (n=5) had elevated H2O2 (median[IQR]: 0.96[0.8-1.4]μM) vs high-controlled (n=11; median[IQR]: 0.5[0.1-0.6]μM) (p=0.002). These latter, exhibited slightly higher H2O2 concentrations than healthy controls (n=16; median[IQR]: 0.4[0.1-0.6]) (p=0.05; p=0.01. Based on ACT, ACQ6, respectively). Conclusions: These preliminary findings suggest that H2O2 is associated with symptoms’ control in severe asthma patients on biologics, hinting at its potential as a stable, objective marker for severe asthma disease monitoring. Subsequent analyses will aim to confirm H2O2 utility in enhancing disease management for severe asthma patients on biologics.
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4404096915